FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1980017839> ?p ?o ?g. }

• W1980017839 endingPage "1267" @default.
• W1980017839 startingPage "1261" @default.
• W1980017839 abstract "Pancreatic cancer is the fourth leading cause of cancer-related death in the western countries and it is resistant to almost all cytotoxic drugs. In the current study, we explored the gemcitabine resistance induced by the interaction between Annexin A2 (ANXA2) and alternatively spliced segment of tenascin-C (TNfnA-D). In the pancreatic cancer cell culture system in vitro, it was proved that exogenous recombinant TNfnA-D combined with the cell surface ANXA2 specifically and their interaction suppressed gemcitabine-induced cytotoxicity on pancreatic cancer cells in a dose-dependent manner. Meanwhile, the TNfnA-D/ANXA2 interaction increased the phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt, inhibitory κB (IκB) kinase α/β (IKKα/β), IκBα, and p65 nuclear factor-κB (NF-κB) significantly. Inhibition of Akt and PI3K with their specific inhibitors partially reversed the suppression of gemcitabine-induced cytotoxicity elicited by TNfnA-D/ANXA2 interaction. Activation of p65 NF-κB was dependent on the phosphorylation of PI3K/Akt. The phosphorylated IKKα/β induced the phosphorylation and degradation of IκBα, the sequential phosphorylation, nuclear translocation and activation of p65 NF-κB. Pyrrolidine dithiocarbamate (PDTC) effectively blocked the activity of p65 NF-κB in response to TNfnA-D. Down-regulation of p65 NF-κB with its specific small interfering RNA (siRNA) restored the gemcitabine-induced cytotoxicity suppressed by TNfnA-D/ANXA2 interaction. For the first time, this study show that ANXA2/TNfnA-D interaction induced gemcitabine resistance via the canonical PI3K/Akt/NF-κB signaling pathways in pancreatic cancer cells. Therefore, therapy targeting ANXA2/TNfnA-D and/or p65 NF-κB may have potential clinical application for patients with pancreatic cancers." @default.
• W1980017839 created "2016-06-24" @default.
• W1980017839 creator A5015574900 @default.
• W1980017839 creator A5015888710 @default.
• W1980017839 creator A5039364613 @default.
• W1980017839 creator A5072983863 @default.
• W1980017839 creator A5090707132 @default.
• W1980017839 date "2010-01-01" @default.
• W1980017839 modified "2023-09-30" @default.
• W1980017839 title "Gemcitabine Resistance Induced by Interaction between Alternatively Spliced Segment of Tenascin-C and Annexin A2 in Pancreatic Cancer Cells" @default.
• W1980017839 cites W1572499404 @default.
• W1980017839 cites W1592768381 @default.
• W1980017839 cites W1797700808 @default.
• W1980017839 cites W1987642268 @default.
• W1980017839 cites W1993885626 @default.
• W1980017839 cites W1996713447 @default.
• W1980017839 cites W1998365542 @default.
• W1980017839 cites W2000932071 @default.
• W1980017839 cites W2014433909 @default.
• W1980017839 cites W2024681421 @default.
• W1980017839 cites W2037482201 @default.
• W1980017839 cites W2043103956 @default.
• W1980017839 cites W2049053145 @default.
• W1980017839 cites W2053546886 @default.
• W1980017839 cites W2090501972 @default.
• W1980017839 cites W2110050868 @default.
• W1980017839 cites W2128042529 @default.
• W1980017839 cites W2149411663 @default.
• W1980017839 cites W2162952272 @default.
• W1980017839 cites W2171190291 @default.
• W1980017839 cites W4242915321 @default.
• W1980017839 doi "https://doi.org/10.1248/bpb.33.1261" @default.
• W1980017839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20686216" @default.
• W1980017839 hasPublicationYear "2010" @default.
• W1980017839 type Work @default.
• W1980017839 sameAs 1980017839 @default.
• W1980017839 citedByCount "37" @default.
• W1980017839 countsByYear W19800178392012 @default.
• W1980017839 countsByYear W19800178392013 @default.
• W1980017839 countsByYear W19800178392014 @default.
• W1980017839 countsByYear W19800178392015 @default.
• W1980017839 countsByYear W19800178392016 @default.
• W1980017839 countsByYear W19800178392017 @default.
• W1980017839 countsByYear W19800178392018 @default.
• W1980017839 countsByYear W19800178392019 @default.
• W1980017839 countsByYear W19800178392020 @default.
• W1980017839 countsByYear W19800178392022 @default.
• W1980017839 countsByYear W19800178392023 @default.
• W1980017839 crossrefType "journal-article" @default.
• W1980017839 hasAuthorship W1980017839A5015574900 @default.
• W1980017839 hasAuthorship W1980017839A5015888710 @default.
• W1980017839 hasAuthorship W1980017839A5039364613 @default.
• W1980017839 hasAuthorship W1980017839A5072983863 @default.
• W1980017839 hasAuthorship W1980017839A5090707132 @default.
• W1980017839 hasBestOaLocation W19800178391 @default.
• W1980017839 hasConcept C100175707 @default.
• W1980017839 hasConcept C11960822 @default.
• W1980017839 hasConcept C121608353 @default.
• W1980017839 hasConcept C126322002 @default.
• W1980017839 hasConcept C153911025 @default.
• W1980017839 hasConcept C184235292 @default.
• W1980017839 hasConcept C185592680 @default.
• W1980017839 hasConcept C190283241 @default.
• W1980017839 hasConcept C2777730290 @default.
• W1980017839 hasConcept C2780210213 @default.
• W1980017839 hasConcept C2780258809 @default.
• W1980017839 hasConcept C30345302 @default.
• W1980017839 hasConcept C502942594 @default.
• W1980017839 hasConcept C55493867 @default.
• W1980017839 hasConcept C62478195 @default.
• W1980017839 hasConcept C71924100 @default.
• W1980017839 hasConcept C75217442 @default.
• W1980017839 hasConcept C86554907 @default.
• W1980017839 hasConcept C86803240 @default.
• W1980017839 hasConcept C88634738 @default.
• W1980017839 hasConcept C96232424 @default.
• W1980017839 hasConceptScore W1980017839C100175707 @default.
• W1980017839 hasConceptScore W1980017839C11960822 @default.
• W1980017839 hasConceptScore W1980017839C121608353 @default.
• W1980017839 hasConceptScore W1980017839C126322002 @default.
• W1980017839 hasConceptScore W1980017839C153911025 @default.
• W1980017839 hasConceptScore W1980017839C184235292 @default.
• W1980017839 hasConceptScore W1980017839C185592680 @default.
• W1980017839 hasConceptScore W1980017839C190283241 @default.
• W1980017839 hasConceptScore W1980017839C2777730290 @default.
• W1980017839 hasConceptScore W1980017839C2780210213 @default.
• W1980017839 hasConceptScore W1980017839C2780258809 @default.
• W1980017839 hasConceptScore W1980017839C30345302 @default.
• W1980017839 hasConceptScore W1980017839C502942594 @default.
• W1980017839 hasConceptScore W1980017839C55493867 @default.
• W1980017839 hasConceptScore W1980017839C62478195 @default.
• W1980017839 hasConceptScore W1980017839C71924100 @default.
• W1980017839 hasConceptScore W1980017839C75217442 @default.
• W1980017839 hasConceptScore W1980017839C86554907 @default.
• W1980017839 hasConceptScore W1980017839C86803240 @default.
• W1980017839 hasConceptScore W1980017839C88634738 @default.
• W1980017839 hasConceptScore W1980017839C96232424 @default.
• W1980017839 hasIssue "8" @default.

• next